View clinical trials related to Untreated Mantle Cell Lymphoma.
Filter by:Primary Objective 1. To evaluate the safety profile of Bevacizumab (Bevacizumabâ„¢)- Rituximab (Rituxan®)-CHOP (RA-CHOP) in patients with newly diagnosed mantle cell lymphoma (MCL). Secondary Objectives 1. To evaluate the response rate and time to disease progression of the RA-CHOP regimen in patients with newly diagnosed MCL. 2. To prospectively characterize the angiogenic profiles of MCL patients during RA-CHOP treatment.